NPPA Fixes Retail Prices For 42 Formulations

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 42 pharmaceutical formulations. These prices are exclusive of Goods and Services Tax, if applicable. These prices were notified on February 7, 2025.

NPPA Approves Separate Pricing for Cipla’s Synchrobreathe Inhaler Device

The National Pharmaceutical Pricing Authority (NPPA) has approved separate pricing for Cipla Ltd.’s “Synchrobreathe Inhaler Device” when used with specific Budesonide and Formoterol formulations. This decision follows recommendations from a Multidisciplinary Committee of Experts and aims to promote incremental innovation in drug delivery.

NPPA Fixes Retail Prices For 65 Formulations

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices for 65 pharmaceutical formulations. The retail price for these specified formulations must match the specified price. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers.

NPPA Revises Ceiling Prices for Scheduled Formulations

The National Pharmaceutical Pricing Authority (NPPA) has issued an order fixing ceiling prices for several essential medicines and revising prices for others based on a review order. The new prices, effective from December 19, 2024, aim to ensure affordability and accessibility of essential drugs.

Anti-Cancer Drugs to Become More Affordable

The National Pharmaceutical Pricing Authority (NPPA) has directed manufacturers to reduce the Maximum Retail Price (MRP) of Trastuzumab, Osimertinib, and Durvalumab. This reduction in MRP is a result of the government’s initiative to exempt these drugs from customs duty and reduce GST rates.